-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cervical cancer is a preventable disease related to HPV virus infection , with high morbidity and mortality worldwide .
Compared with cytological screening , primary
HPV testing is more sensitive in detecting cervical precancerous lesions , and can be detected using DNA or RNA- based testing methods
.
It is not clear whether these tests are equally effective in the long term, especially in women with negative HPV test results
Cervical cancer is a preventable disease related to HPV virus infection , with high morbidity and mortality worldwide .
Cytological screening compared with primary
The purpose of this study is to investigate the long-term safety of
HPV- negative patients .
In this study, eligible participants had at least one HPV- negative result and one or more cytological screenings after the examination ( 9509 participants underwent basic DNA testing, 3473 participants underwent DNA and RNA Basic testing)
The purpose of this study is to investigate HPV.
The purpose of this study is to investigate the long-term safety of
The overall test surfaced that among HPV- negative participants, there was no significant difference in the long-term risk of CIN2 , CIN3 or higher , regardless of whether DNA or RNA- based human papillomavirus detection methods were used .
We can be sure, for respect for the results to detect HPV-negative women, DNA and RNA analysis showed that within a few years are similar, simply put, is the probability of future HPV-negative people suffering from cervical cancer is relatively low .
Women who have a negative HPV test have similar results from DNA and RNA tests within a few years.
According to the test analysis, among the participants who were HPV- negative at the baseline examination, the cumulative incidence of CIN2 and CIN3 during the 120 -month follow-up period was shown in the figure, and there was no significant difference between the two groups .
According to the test analysis, among the participants who were HPV- negative at the baseline examination, the cumulative incidence of CIN2 and CIN3 during the 120 -month follow-up period was shown in the figure, and there was no significant difference between the two groups .
Diagnosis As HPV-based screening programs increasingly rely on genotyping classifications that HC2 does not provide, it is important to recognize the overall equivalent performance of other HPV testing and analysis
References: Strangc M, Gottschlich DA, Cook M, et al.
Long-term cervical precancer outcomes after a negative DNA- or RNA-based human papillomavirus result [J].
American Journal of Obstetrics and Gynecology, 2021.
Long-term cervical precancer outcomes after a negative DNA- or RNA -based human papillomavirus result in this message
